Biosimilar Elimination Red Tape Act
In November 2022, Sen. Mike Lee (R-UT) introduced the Biosimilar Elimination Red Tape Act that would prohibit the FDA from requiring that biosimilars undergo switching studies.
In November 2022, Sen. Mike Lee (R-UT) introduced the Biosimilar Elimination Red Tape Act that would prohibit the FDA from requiring that biosimilars undergo switching studies.